Veryan Medical
Veryan Medical is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Veryan Medical.
Veryan Medical is a company.
Key people at Veryan Medical.
Veryan Medical is a medical device company specializing in innovative vascular stents, particularly the BioMimics 3D Vascular Stent System, a nitinol-based, self-expanding stent with a unique 3D helical geometry designed to mimic natural vessel blood flow and improve clinical outcomes in peripheral artery disease.[1][5] It serves interventional cardiologists and vascular surgeons treating patients with vascular disease, addressing the problem of restenosis and poor patency in stented arteries by promoting swirling blood flow that reduces turbulence and enhances healing.[1][5] As a spin-out from Imperial College London acquired by Otsuka Medical Devices in 2018, Veryan benefits from strong R&D support and has demonstrated growth through clinical programs like the MIMICS-3D registry, showing 3-year results comparable to drug-eluting stents.[1][5]
Veryan Medical originated as a technology spin-out from Imperial College London in 2005, stemming from pioneering research by Professor Colin Caro, Emeritus Professor of Physiological Mechanics in the Department of Bioengineering, on the relationship between vessel geometry, blood flow mechanics, and vascular disease.[1] Incorporated on 10 June 2003 as VERYAN MEDICAL LIMITED (company number 04793815), the company leveraged this expertise to develop and patent the BioMimics 3D stent system.[1][2] A pivotal moment came in 2018 when it was acquired by Otsuka Medical Devices, part of the global Otsuka group, providing resources for expanded clinical, regulatory, and commercial efforts while maintaining its UK base in Horsham, West Sussex.[1][3]
Veryan rides the trend of bio-mimetic medical devices in interventional cardiology, where stents evolve from rigid, cylindrical designs to those mimicking natural vascular anatomy to improve long-term patency amid rising peripheral artery disease prevalence driven by aging populations and diabetes.[1][5] Timing aligns with advancements in nitinol self-expanding stents and real-world evidence from registries like MIMICS-3D, which validate alternatives to drug-eluting technologies amid concerns over drug-related complications.[5] Market forces favoring minimally invasive endovascular therapies boost Veryan, especially under Otsuka's global umbrella, influencing the ecosystem by setting benchmarks for helical centerline stents and enabling combinations with DCBs for optimized outcomes.[1][5]
Veryan is poised for expanded adoption of the BioMimics 3D system, with ongoing MIMICS data and potential US market growth under Otsuka's distribution, targeting below-the-knee applications and further DCB synergies.[5] Trends like personalized vascular therapies and AI-optimized stent designs will shape its path, potentially evolving its influence through new iterations or acquisitions that amplify its swirling flow innovation. This positions Veryan as a key player delivering practical solutions to daily physician challenges in vascular intervention.[1]
Key people at Veryan Medical.
